Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves
Source: SeekingAlpha
2026-02-11 13:55:14 ET
More on Veru
- Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
- Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
- Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance
- Seeking Alpha’s Quant Rating on Veru
- Historical earnings data for Veru
Read the full article on Seeking Alpha
For further details see:
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves
Veru Inc.
NASDAQ: VERU
VERU Trading
126.7% G/L:
$5.2594 Last:
43,515,298 Volume:
$2.18 Open:
VERU Latest News
VERU Stock Data
$37,718,252
13,610,671
1.25%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Miami
